GMP Close-out Letter Program Shows Few Benefits After 20 Months
Executive Summary
More than 20 months after FDA Commissioner Margaret Hamburg announced with much fanfare that the agency would issue "close-out letters" to companies that had received FDA warning letters once they had addressed the problems inspectors found, the program has yet to fulfill its promise of offering sponsors a reliable, public way of resolving regulatory problems.
You may also be interested in...
Impax Transferring Products To Taiwan After GMP Warning Letter For U.S. Plant
Impax Laboratories says it has been transferring important products from a Hayward, Calif. manufacturing facility targeted by a U.S. FDA warning letter to a new facility in Taiwan as it works to resolve regulatory issues in the U.S. plant and prepare for a re-inspection
Impax Transferring Products To Taiwan After GMP Warning Letter For U.S. Plant
Future applications involving the Hayward, Calif. plant targeted by warning letter on manufacturing practices may be stalled, but Phase III Parkinson's candidate IPX066 won't be affected, execs say.
GMP Violations Are A Consistent But Well-Shuffled Deck, FDA Data Show
The same five sets of cGMP violations have shown up for at least the past five fiscal years when FDA inspects drug manufacturers, according to a database the agency recently made public.